JP2006117697A5 - - Google Patents

Download PDF

Info

Publication number
JP2006117697A5
JP2006117697A5 JP2006002633A JP2006002633A JP2006117697A5 JP 2006117697 A5 JP2006117697 A5 JP 2006117697A5 JP 2006002633 A JP2006002633 A JP 2006002633A JP 2006002633 A JP2006002633 A JP 2006002633A JP 2006117697 A5 JP2006117697 A5 JP 2006117697A5
Authority
JP
Japan
Prior art keywords
leu
peptide
amino acids
peptide according
hydrophobic amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006002633A
Other languages
English (en)
Japanese (ja)
Other versions
JP4522367B2 (ja
JP2006117697A (ja
Filing date
Publication date
Priority claimed from AUPN0590A external-priority patent/AUPN059095A0/en
Priority claimed from AUPN0589A external-priority patent/AUPN058995A0/en
Application filed filed Critical
Publication of JP2006117697A publication Critical patent/JP2006117697A/ja
Publication of JP2006117697A5 publication Critical patent/JP2006117697A5/ja
Application granted granted Critical
Publication of JP4522367B2 publication Critical patent/JP4522367B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006002633A 1995-01-16 2006-01-10 新規ペプチド Expired - Fee Related JP4522367B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN0590A AUPN059095A0 (en) 1995-01-16 1995-01-16 Novel lipopeptide
AUPN0589A AUPN058995A0 (en) 1995-01-16 1995-01-16 Novel peptide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005034053A Division JP2005145985A (ja) 1995-01-16 2005-02-10 新規ペプチド

Publications (3)

Publication Number Publication Date
JP2006117697A JP2006117697A (ja) 2006-05-11
JP2006117697A5 true JP2006117697A5 (https=) 2006-11-09
JP4522367B2 JP4522367B2 (ja) 2010-08-11

Family

ID=25644844

Family Applications (3)

Application Number Title Priority Date Filing Date
JP52191796A Expired - Fee Related JP3665342B2 (ja) 1995-01-16 1996-01-16 新規ペプチド
JP2005034053A Pending JP2005145985A (ja) 1995-01-16 2005-02-10 新規ペプチド
JP2006002633A Expired - Fee Related JP4522367B2 (ja) 1995-01-16 2006-01-10 新規ペプチド

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP52191796A Expired - Fee Related JP3665342B2 (ja) 1995-01-16 1996-01-16 新規ペプチド
JP2005034053A Pending JP2005145985A (ja) 1995-01-16 2005-02-10 新規ペプチド

Country Status (8)

Country Link
US (1) US6057294A (https=)
EP (1) EP0804469B1 (https=)
JP (3) JP3665342B2 (https=)
AU (1) AU694602B2 (https=)
CA (1) CA2210812C (https=)
DE (1) DE69617396T2 (https=)
ES (1) ES2168456T3 (https=)
WO (1) WO1996022306A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2168456T3 (es) * 1995-01-16 2002-06-16 North Sydney Area Health Serv Peptidos que afectan a los linfocitos t.
AU2020497A (en) * 1996-03-27 1997-10-17 Susan R. George Receptor and transporter antagonists
WO1997047644A1 (en) * 1996-06-11 1997-12-18 Northern Sydney Area Health Services T cell antigen receptor peptides
US20050070478A1 (en) * 1996-06-11 2005-03-31 Northern Sydney Area Health Services T cell antigen receptor peptides
US6696545B1 (en) 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
IL132310A0 (en) * 1997-04-11 2001-03-19 Sangstat Medical Corp Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
AU2001249067A1 (en) * 2000-05-19 2001-12-03 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes
AU2003210659A1 (en) 2002-01-24 2003-09-02 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
WO2005115430A1 (en) * 2004-05-27 2005-12-08 Gropep Limited Treatment of inflammatory airway disease
EP1945658A4 (en) * 2005-09-22 2012-05-30 Yeda Res & Dev DIASTEREOMERS PEPTIDES FOR MODULATING T-CELL IMMUNITY
EP1870420A1 (en) * 2006-06-23 2007-12-26 Max-Delbrück-Centrum Für Molekulare Medizin Peptides regulating the surface expression of the T cell receptor
US20120077732A1 (en) * 2008-11-24 2012-03-29 Sydney West Area Health Service Cyclic peptides and uses thereof
US10138276B2 (en) 2009-09-30 2018-11-27 Signablok, Inc. Inhibition of TCR signaling with peptide variants
US8513185B2 (en) 2009-10-13 2013-08-20 Alexander B. Sigalov Inhibition of TREM receptor signaling with peptide variants
WO2018183888A2 (en) 2017-03-31 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
CA3109702A1 (en) 2018-08-13 2020-02-20 Signablok, Inc. Peptides and compositions for targeted treatment and imaging

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
US5223485A (en) * 1989-01-31 1993-06-29 Abbott Laboratories Anaphylatoxin-receptor ligands
CA2045578A1 (en) * 1989-01-31 1990-08-01 Megumi Kawai Anaphylatoxin-receptor ligands
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
AU8228791A (en) * 1990-06-15 1992-01-07 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
US5387671A (en) * 1990-12-27 1995-02-07 Abbott Laboratories Hexa- and heptapeptide anaphylatoxin-receptor ligands
CN1118572A (zh) * 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
AU1681095A (en) * 1994-01-14 1995-08-01 Matthias Rath Hydrophilic signal oligopeptides and methods of therapeutic use
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
AU2238395A (en) * 1994-04-01 1995-10-23 Immulogic Pharmaceutical Corporation Haptenated peptides and uses thereof
ES2168456T3 (es) * 1995-01-16 2002-06-16 North Sydney Area Health Serv Peptidos que afectan a los linfocitos t.
US5753625A (en) * 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease

Similar Documents

Publication Publication Date Title
JP2006117697A5 (https=)
JPWO2020209285A5 (https=)
JP2012525844A5 (https=)
JP2009504157A5 (https=)
MX2007013031A (es) Agentes terapeuticos de peptidos de toxina.
JP2010519252A5 (https=)
JP2013537907A5 (https=)
JP2010515686A5 (https=)
JP2008541759A5 (https=)
JP2006506942A5 (https=)
JP2017160222A5 (https=)
TW200833840A (en) Toxin peptide therapeutic agents
JP2009537143A5 (https=)
JP2007530577A5 (https=)
JP2018515101A5 (https=)
JP2011528332A5 (https=)
JP2009511579A5 (https=)
JP2011511753A5 (https=)
JP2005516885A5 (https=)
JP2014527040A5 (https=)
JP2014532722A5 (https=)
RU2011121971A (ru) Пептиды-производные ил-4 для модуляции хронического воспалительного ответа и лечения аутоиммунных заболеваний
JP2010513327A5 (https=)
RU2014105513A (ru) Противофиброзные пептиды и их применение в способах лечения заболеваний и расстройств, характеризующихся фиброзом
JP2014529399A5 (https=)